A novel rabies vaccine based on a recombinant parainfluenza virus 5 expressing rabies virus glycoprotein

Journal of Virology

Volumn 87, Issue 6, 2013, Pages 2986-2993

  Chen, Zhenhai ^a   Zhou, Ming ^a   Gao, Xiudan ^a   Zhang, Guoqing ^a   Ren, Guiping ^a   Gnanadurai, Clement W ^a   Fu, Zhen F ^a,b   He, Biao ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b HUAZHONG AGRICULTURAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

RABIES VACCINE; VIRUS GLYCOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; MOUSE; NEWBORN; NONHUMAN; PARAINFLUENZA VIRUS; PARAINFLUENZA VIRUS 5; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION; RABIES; SINGLE DRUG DOSE; SURVIVAL RATE; VACCINATION; VIRUS RECOMBINANT;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ANIMALS; ANTIGENS, VIRAL; DISEASE MODELS, ANIMAL; DRUG CARRIERS; GENETIC VECTORS; GLYCOPROTEINS; INJECTIONS, INTRAMUSCULAR; MICE; RABIES; RABIES VACCINES; RECOMBINANT PROTEINS; RESPIROVIRUS; SURVIVAL ANALYSIS; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS;

EID: 84874706789     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02886-12     Document Type: Article

References (42)

1. Rupprecht CE, Willoughby R, Slate D. 2006. Current and future trends in the prevention, treatment and control of rabies. Expert Rev. Anti Infect. Ther. 4:1021-1038.
2. Martinez L. 2000. Global infectious disease surveillance. Int. J. Infect. Dis. 4:222-228.
3. WHO.2005. First report of theWHOExpert Committee on Rabies. Technical Report Series 931. WHO, Geneva, Switzerland.
4. WHO. 2002. World survey for rabies no 35 for the year 1999. Report WHO/CD/CSR/EPH/2002 10. WHO, Geneva, Switzerland.
5. Knobel DL, Cleaveland S, Coleman PG, Fevre EM, Meltzer MI, Miranda ME, Shaw A, Zinsstag J, Meslin FX. 2005. Re-evaluating the burden of rabies in Africa and Asia. Bull. World Health Organ. 83:360-368.
6. Wu X, Smith TG, Rupprecht CE. 2011. From brain passage to cell adaptation: the road of human rabies vaccine development. Expert Rev. Vaccines 10:1597-1608.
7. Kieny MP, Lathe R, Drillen R, Spehner D, Skory S, Schmitt D, Wiktor T, Koprowski H, Lecocq JP. 1984. Expression of RV glycoprotein from a recombinant vaccinia virus. Nature 312:163-166.
8. Meslin FX, Fisbein DB, Matter HC. 1994. Rationale and prospects for rabies elimination in developing countries. Curr. Top. Microbiol. Immunol. 187:1-26.
9. Wiktor TJ, Macfarlan RI, Reagan KJ, Dietzschold B, Curtis PJ, Wunner WH, Kieny MP, Lathe R, Lecocq JP, Mackett M, et al. 1984. Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. Proc. Natl. Acad. Sci. U. S. A. 81:7194-7198.
10. Murray KO, Holmes KC, Hanlon CA. 2009. Rabies in vaccinated dogs and cats in the United States, 1997-2001. J. Am. Vet. Med. Assoc. 235:691-695.
11. Rupprecht CE, Smith BLK, Orciari LA, Niezgoda M, Whitfield SG, Gibbons RV, Guerra M, Hanlon CA. 2001. Human infection due to recombinant vaccinia-rabies glycoprotein virus. N. Engl. J. Med. 345:582-586.
12. Tolson ND, Charlton KM, Stewart RB, Campbell JB, Wiktor TJ. 1987. Immune response in skunks to a vaccinia virus recombinant expressing the rabies virus glycoprotein. Can. J. Vet. Res. 51:363-366.
13. Artois M, Guittre C, Thomas I, Leblois H, Brochier B, Barrat J. 1992. Potential pathogenicity for rodents of vaccines intended for oral vaccination against rabies: a comparison. Vaccine 10:524-528.
14. Fehlner-Gardiner C, Nadin-Davis S, Armstrong J, Muldoon F, Bachmann P, Wandeler A. 2008. Era vaccine-derived cases of rabies in wildlife and domestic animals in Ontario, Canada, 1989-2004. J. Wildl. Dis. 44: 71-85.
15. CDC. 2009. Human vaccinia infection after contact with a raccoon rabies vaccine bait-Pennsylvania 2009. MMWR Morb. Mortal. Wkly. Rep. 58: 1204-1207.
16. Rupprecht CE, Charlton KM, Artois M, Casey GA, Webster WA, Campbell JB, Lawson KF, Schneider LG. 1990. Ineffectiveness and comparative pathogenicity of attenuated rabies virus vaccines for the striped skunk (Mephitis mephitis). J. Wildl. Dis. 26:99-102.
17. Weyer J, Rupprecht CE, Nel LH. 2009. Poxvirus-vectored vaccines for rabies-a review. Vaccine 27:7198-7201.
18. Finke S, Conzelmann KK. 2005. Replication strategies of rabies virus. Virus Res. 111:120-131.
19. Cox JH, Dietzschold B, Schneider LG. 1977. Rabies virus glycoprotein. II. Biological and serological characterization. Infect. Immun. 16:754-759.
20. Tompkins SM, Lin Y, Leser GP, Kramer KA, Haas DL, Howerth EW, Xu J, Kennett MJ, Durbin RK, Durbin JE, Tripp R, Lamb RA, He B. 2007. Recombinant parainfluenza virus 5 (PIV5) expressing the influenza A virus hemagglutinin provides immunity in mice to influenza A virus challenge. Virology 362:139-150.
21. Sarmento L, Tseggai T, Dhingra V, Fu ZF. 2006. Rabies virus-induced apoptosis involves caspase-dependent and caspase-independent pathways. Virus Res. 121:144-151.
22. He B, Paterson RG, Ward CD, Lamb RA. 1997. Recovery of infectious SV5 from cloned DNA and expression of a foreign gene. Virology 237: 249-260.
23. Wen Y, Wang H, Wu H, Yang F, Tripp RA, Hogan RJ, Fu ZF. 2011. Rabies virus expressing dendritic cell-activating molecules enhances the innate and adaptive immune response to vaccination. J. Virol. 85:1634-1644.
24. Chen Z, Lawson S, Sun Z, Zhou X, Guan X, Christopher-Hennings J, Nelson EA, Fang Y. 2010. Identification of two auto-cleavage products of nonstructural protein 1 (nsp1) in porcine reproductive and respiratory syndrome virus infected cells: nsp1 function as interferon antagonist. Virology 398:87-97.
25. Timani KA, Sun D, Sun M, Keim C, Lin Y, Schmitt PT, Schmitt AP, He B. 2008. A single amino acid residue change in the P protein of parainfluenza virus 5 elevates viral gene expression. J. Virol. 82:9123-9133.
26. Sun D, Xu P, He B. 2011. Sumoylation of the P protein at K254 plays an important role in growth of parainfluenza virus 5. J. Virol. 85:10261-10268.
27. Smith LT, Yager PA, Baer GM. 1996. A rapid fluorescence focus inhibition test (RFFIT) for determining rabies virus-neutralising antibody. In Meslin FX, Kaplan MM, Koproski H (ed), Laboratory techniques in rabies, 4th ed. WHO, Geneva, Switzerland.
28. Reed LJ, Muench H. 1938. A simple method of estimating fifty per cent endpoints. Am. J. Hyg. 27:493-497.
29. Ge J, Wang X, Tao L, Wen Z, Feng N, Yang S, Xia X, Yang C, Chen H, Bu Z. 2011. Newcastle disease virus-vectored rabies vaccine is safe, highly immunogenic, and provides long-lasting protection in dogs and cats. J. Virol. 85:8241-8252.
30. Wunner WH. 2002. Rabies virus. Academic Press, New York, NY.
31. Monaco F, Franchi PM, Lelli R. 2006. Studies on an inactivated vaccine against rabies virus in domestic animals. Dev. Biol. (Basel) 125:233-239.
32. Li J, Faber M, Papaneri A, Faber ML, McGettigan JP, Schnell MJ, Dietzschold B. 2006. A single immunization with a recombinant canine adenovirus expressing the rabies virusGprotein confers protective immunity against rabies in mice. Virology 356:147-154.
33. Tordo N, Foumier A, Jallet C, Szelechowski M, Klonjkowski B, Eloit M. 2008. Canine adenovirus based rabies vaccines. Dev. Biol. (Basel) 131: 467-476.
34. Weyer J, Rupprecht CE, Mans J, Viljoen GJ, Nel LH. 2007. Generation and evaluation of a recombinant modified vaccinia virus Ankara vaccine for rabies. Vaccine 25:4213-4222.
35. Zhou D, Cun A, Li Y, Xiang Z, Ertl HC. 2006. A chimpanzee-origin adenovirus vector expressing the rabies virus glycoprotein as an oral vaccine against inhalation infection with rabies virus. Mol. Ther. 14:662-672.
36. Gaudin Y, Ruigrok RW, Tuffereau C, Knossow M, Flamand A. 1992. Rabies virus glycoprotein is a trimer. Virology 187:627-632.
37. Whitt MA, Buonocore L, Prehaud C, Rose JK. 1991. Membrane fusion activity, oligomerization, and assembly of the rabies virus glycoprotein. Virology 185:681-688.
38. Mooney A, Li Z, Gabbard JD, He B, Tompkins SM. 2013. Recombinant parainfluenza virus 5 vaccine encoding the influenza virus hemagglutinin protects against H5N1 highly pathogenic avian influenza virus following intranasal or intramuscular vaccination of BALB/c mice. J. Virol. 87:363-371.
39. Chen Z, Xu P, Salyards GW, Harvey SB, Rada B, Fu ZF, He B. 2012. Evaluating a parainfluenza virus 5-based vaccine in a host with preexisting immunity against parainfluenza virus 5. PLoS One 7:e50144. doi: 10.1371/journal.pone.0050144.
40. Faber M, Dietzschold B, Li J. 2009. Immunogenicity and safety of recombinant rabies viruses used for oral vaccination of stray dogs and wildlife. Zoonoses Public Health 56:262-269.
41. Li Z, Mooney A, Gabbard JD, Gao X, Xu P, Place RJ, Hogan RJ, Tompkins SM, He B. 2013. Recombinant parainfluenza virus 5 expressing hemagglutinin of influenzaAvirus H5N1 protected mice against lethal high pathogenic avian influenza virus H5N1 challenge. J. Virol. 87:354-362.
42. Dietzschold B, Wang HH, Rupprecht CE, Celis E, Tollis M, Ertl H, Heber-Katz E, Koprowski H. 1987. Induction of protective immunity against rabies by immunization with rabies virus ribonucleoprotein. Proc. Natl. Acad. Sci. U. S. A. 84:9165-9169.